Head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic CRPC

The approval of enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) provided an important life-extending drug. Now the sequencing and uses of enzalutamide are bei... Author: VJOncology Added: 02/16/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts